Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki^#¹, Igor Odintsov^#^{2

3

4}, Keiji Ishida⁵, Allan J W Lui^{2

6}, Masanori Kato⁵, Tatsuya Suzuki⁵, Tom Zhang², Kentaro Wakayama⁵, Renate I Kurth², Ryan Cheng², Hidenori Fujita⁵, Lukas Delasos^{2

7}, Morana Vojnic^{2

3

8}, Inna Khodos⁹, Yukari Yamada⁵, Kota Ishizawa^{3

10}, Marissa S Mattar², Kaoru Funabashi⁵, Qing Chang⁹, Shuichi Ohkubo⁵, Wakako Yano⁵, Ryuichiro Terada⁵, Claudio Giuliano¹¹, Yue Christine Lu², Annalisa Bonifacio¹¹, Siddharth Kunte^{2

12}, Monika A Davare¹³, Emily H Cheng³, Elisa de Stanchina⁹, Emanuela Lovati¹¹, Yoshikazu Iwasawa⁵, Marc Ladanyi^{2

3}, Romel Somwar^{14

15}

Affiliations

¹ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.
² Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
⁶ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
⁷ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
⁸ Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA.
⁹ Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
¹¹ Helsinn Healthcare SA, Lugano, Switzerland.
¹² Dana Cancer Center, Toledo, OH, USA.
¹³ Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.
¹⁴ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.
¹⁵ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.

^# Contributed equally.

Published Erratum

Isao Miyazaki et al. Nat Cancer. 2023 Oct.

. 2023 Oct;4(10):1526.

doi: 10.1038/s43018-023-00663-3.

¹ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.
² Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
⁶ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
⁷ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
⁸ Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA.
⁹ Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
¹¹ Helsinn Healthcare SA, Lugano, Switzerland.
¹² Dana Cancer Center, Toledo, OH, USA.
¹³ Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.
¹⁴ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.
¹⁵ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.

^# Contributed equally.

No abstract available

Erratum for

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37743366 Free PMC article.